We have launched our mobile app, get it now. Call : 9354229384, 9354252518, 9999830584.  

Current Affairs

Cabotegravir and rilpivirine

Date: 23 November 2021 Tags: Miscellaneous

Issue

UK’s National Institute for Health and Care Excellence (NICE) has recommended injectable drugs for treatment of HIV-1 infection in adults.

 

Background

The injectable drugs are cabotegravir (Vocabria), made by Viiv Healthcare along with rilpivirine (Rekambys), made by Janssen.

 

 

Details

  • HIV infection has no cure and patients are forced to manage their disease with the help of medication. 

  • Patients have to take antiretroviral tablets everyday for the rest of their lives. The medication will keep viral loads to levels at which the infection cannot be detected and spread between individuals.

 

Issues of medication

Taking tablets daily can be difficult because of drug-related side effects, toxicity, and other issues such as stigma or changes in lifestyle.

 

Role of new drugs

  • Cabotegravir with rilpivirine is as effective as oral antiretrovirals as it keeps viral load to a manageable role.

  • These drugs can be given to adult HIV patients after antiretroviral medicines have kept viral loads to low levels and virus is not showing resistance.

  • Initially oral tablets have to be given to such patients after which the injections are to be administered separately every two months.

 

HIV AIDS

  • Human immunodeficiency Virus causes a disease known as Acquired Immunodeficiency Syndrome in which immune system of an individual becomes weak.

  • The disease is incurable and the treatment involves reducing the viral load to prevent it from attacking body immune system.

 

Spread

  • Blood transfusion

  • Contact with body fluid

  • Unprotected sexual intercourse

  • Mother to baby during pregnancy

  • Sharing syringes

 

Symptoms

  • Rapid weight loss

  • Recurring fever

  • Tiredness

  • Long lasting diarrhea

  • Sores in mouth

  • Swelling in lymph glands

  • Abdominal pain